Lead Independent Director
Douglas A. Treco, Ph.D.
Dr. Doug Treco has served on our Board of Directors since June 2020. Dr. Treco co-founded Ra Pharmaceuticals, Inc. in 2008 and served as Chief Executive Officer and a member of the Board of Directors from its inception until its acquisition by UCB in April 2020. He was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT), a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc in 2005. Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. He received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital. We believe Dr. Treco’s experience as an executive and scientific leader in the life sciences industry, in particular, his unique focus on rare disease, gene targeting, and gene therapy, qualifies him to serve on our Board of Directors.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.